Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.

Filter by Species:

Filter by Pathway Type:

Select Pathway Sub-Category:

Select Pathway Sub-Category:



Showing 21 - 30 of 110239 pathways
PathBank ID Pathway Chemical Compounds Proteins

SMP0120659

Pw121915 View Pathway
Metabolite

2-Hydroxyglutric Aciduria (D and L Form)

Rattus norvegicus
L-2-Hydroxyglutaric Aciduria (D-2-Hydroxyglutaric Aciduria ) is an autosomal recessive disease caused by a mutation in the L2HGDH gene which codes for L-2-Hydroxygluarate dehydrogenase. A deficiency in this enzyme results in accumulation of L-2-Hydroxyglutaric acid in plasma, spinal fluid, and urine; and L-lysine in plasma and spinal fluid. Symptoms, which present at birth, include ataxia, hypotonia, mental retardation, and seizures. Premature death often results. D-2-Hydroxyglutaric Aciduria is an autosomal recessive disease caused by a mutation in the D2HGDH gene which does for D-2-Hydroxygluarate dehydrogenase. A deficiency in this enzyme results in accumulation of D-2-Hydroxyglutaric acid in plasma, spinal fluid, and urine; oxoglutaric acid in urine; and gabba-aminobutyric acid in spinal fluid. Symptoms, which present at birth, include ataxia, hypotonia, mental retardation, and seizures. Premature death often results.

Disease

SMP0000549

Pw000525 View Pathway
Metabolite

2-Ketoglutarate Dehydrogenase Complex Deficiency

Homo sapiens
2-Ketoglutarate dehydrogenase complex deficiency is a rare autosomal recessive disease. 2-ketoglutarate dehydrogenase is an enzyme of the Krebs cycle that catalyzes the oxidation of alpha-ketoglutarate to succinyl CoA. The deficiency of 2-Ketoglutarate dehydrogenase complex results in the disorder of Krebs cycle with accumulation of succinyl CoA. The primary manifestations include developmental delay, ataxia, opisthotonus, seizure and other neurological symptoms.

Disease

SMP0120832

Pw122093 View Pathway
Metabolite

2-Ketoglutarate Dehydrogenase Complex Deficiency

Rattus norvegicus
2-Ketoglutarate dehydrogenase complex deficiency is a rare autosomal recessive disease. 2-ketoglutarate dehydrogenase is an enzyme of the Krebs cycle that catalyzes the oxidation of alpha-ketoglutarate to succinyl CoA. The deficiency of 2-Ketoglutarate dehydrogenase complex results in the disorder of Krebs cycle with accumulation of succinyl CoA. The primary manifestations include developmental delay, ataxia, opisthotonus, seizure and other neurological symptoms.

Disease

SMP0120613

Pw121869 View Pathway
Metabolite

2-Ketoglutarate Dehydrogenase Complex Deficiency

Mus musculus
2-Ketoglutarate dehydrogenase complex deficiency is a rare autosomal recessive disease. 2-ketoglutarate dehydrogenase is an enzyme of the Krebs cycle that catalyzes the oxidation of alpha-ketoglutarate to succinyl CoA. The deficiency of 2-Ketoglutarate dehydrogenase complex results in the disorder of Krebs cycle with accumulation of succinyl CoA. The primary manifestations include developmental delay, ataxia, opisthotonus, seizure and other neurological symptoms.

Disease

SMP0120660

Pw121916 View Pathway
Metabolite

2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency

Rattus norvegicus
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.

Disease

SMP0120439

Pw121690 View Pathway
Metabolite

2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency

Mus musculus
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.

Disease

SMP0000137

Pw000061 View Pathway
Metabolite

2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency

Homo sapiens
2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency (Hydroxyl-CoA dehydrogenase deficiency; MHBD) is a rare inborn disease of metabolism caused by a mutation in the HSD17B10 gene which codes for 3-hydroxyacyl-CoA dehydrogenase type-2. A deficiency in this enzyme results in accumulation of L-lactic acid in blood, spinal fluid, and urine; 2-ethylhydracrylic acid, 2-methyl-3-hydroxybutyric acid, and tiglylglycine in urine. Symptoms include cerebal atrophy, motor and mental retardation, overactivity and behavior issues, seizures and progressive neurological defects leading to early death. Treatment includes a high carbohydrate and low protein diet.

Disease

SMP0002108

Pw002096 View Pathway
Metabolite

2-O-alpha-Mannosyl-D-glycerate Degradation

Escherichia coli
2-O-α-Mannosyl-D-glycerate (MG; also named as Alpha-Mannosylglycerate) is an organic compound that will affect the osmosis in hyperthermophilic archaea and bacteria. In E.coli, 2-O-α-mannosyl-D-glycerate PTS permease (mngA) import MG into cell, and then phosphorylate MG to 2-O-(6-phospho-α-mannosyl)-D-glycerate by phosphocarrier protein HPr. 2-O-(6-phospho-α-mannosyl)-D-glycerate is converted to glyceric acid as well as mannose 6-phosphate by alpha-mannosidase mngB. Finally, glyceric acid is catalyzed to 2-Phospho-D-glyceric acid with ATP as energy source by Glycerate kinase 2. E.coli can't use MG as osmotic stress protection, but it can use MG as a carbon source.

Metabolic

SMP0002120

Pw002108 View Pathway
Metabolite

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Escherichia coli
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)

Metabolic

SMP0122264

Pw123572 View Pathway
Metabolite

2-Oxoglutarate Decarboxylation to Succinyl-CoA

Pseudomonas aeruginosa
2-oxoglutarate dehydrogenase complex is consisted of oxoglutarate decarboxylase, dihydrolipoyl succinyltransferase and dihydrolipoyl dehydrogenase), which is a rate-limiting enzyme of the citric acid cycle (TCA cycle) in prokaryote. The reaction that catalyzed by 2-oxoglutarate dehydrogenase complex can be generalized as 2-oxoglutarate + coenzyme A + NAD+ → succinyl-CoA + CO2 + NADH. During the OGDHC reaction cycle, 2-oxoglutarate is bound and decarboxylated by E1(o), a thiamin-diphosphate cofactor containing enzyme. The succinyl group is transferred to the lipoyl domain of E2(o) where it is carried to the active site and transferred to coenzyme A, forming succinyl-CoA. During this transfer the lipoyl group is reduced to dihydrolipoyl. The succinyl-CoA is released and the lipoyl domain of E2(o) is oxidized by E3 via transfer of protons to NAD, forming NADH and regenerating the lipoyl group back to lipoyllysine for another cycle. Under aerobic growth conditions the OGDHC not only catalyzes a key reaction in the TCA cycle, it also provides succinyl-CoA for methionine and lysine biosynthesis, the latter pathway also leading to peptidoglycan biosynthesis. The synthesis of the OGDHC is repressed by anaerobiosis and is also subject to glucose repression. It is induced by aerobic growth on acetate. (EcoCyc)

Metabolic
Showing 21 - 30 of 110239 pathways